Is Syntara Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Syntara Ltd (SNT.AX) is currently classified as DOUBTFUL as of April 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Syntara Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Syntara Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Syntara Ltd?

Muslim investors may consider investing in Syntara Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Syntara Ltd classified as DOUBTFUL?

Musaffa determines the Shariah status of Syntara Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Syntara Ltd updated?

The Shariah compliance status of Syntara Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Syntara Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Syntara Ltd?

You can check the latest Shariah compliance status of Syntara Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

SNT.AX Shariah Compliance

Screening Methodology: AAOIFI

DOUBTFUL

Last Updated: April 15, 2025

Report Source: 2025 2nd Quarter Report

Analyst's Ratings for Syntara Ltd (SNT.AX)

Based on 6 analysts giving stock ratings to Syntara Ltd in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Syntara Ltd. Stock Analysis SNT.AX

Australia Health Care Nano Cap Report: Q2, 2025

Syntara Ltd. is a clinical stage drug development company which engages in the development of healthcare products for haematological diseases. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. The firm is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The firm is also advancing topical pan-LOX inhibitors in scar revision, keloid scarring and scar prevention post-surgery. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.

Key Statistics of Syntara Ltd (SNT.AX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

AUD0.03AUD0.03

Today's Open

AUD0.03

Volume

2.07M

P/E Ratio (TTM)

52 Week Range

AUD0.02AUD0.08

Market Cap

45.76M

Avg. Volume

2.12M

Dividend Yield

Financial Metrics & Statements of Syntara Ltd (SNT.AX)

FAQ's for Syntara Ltd (SNT.AX)

According to Musaffa’s Shariah screening methodology, Syntara Ltd (SNT.AX) is currently classified as DOUBTFUL as of April 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.